Charles River Labs shares target cut by Baird amid tempered growth view By Investing.com

On Wednesday, Baird, a financial services firm, adjusted its outlook on Charles River Laboratories (NYSE: CRL) shares, reducing the price target to $239.00 from the previous $271.00. Despite this change, the firm maintained its Outperform rating on the company’s stock.

The revision reflects a more cautious stance regarding the company’s performance in the second half of the year. The analyst at Baird expressed a tempered view of the upcoming ramp in business, leading to lowered estimates for the latter half of the year as well as a recalibrated valuation.

The expectation is that the second quarter results will be satisfactory, and the firm’s long-term perspective on Charles River Labs (NYSE:) remains positive, with anticipation of stability, growth, and potential for multiple expansion beginning in 2025 and beyond.

The commentary from Baird highlighted that while surprises from Charles River Labs could still occur, achieving the lower end of the company’s 2024 guidance may require either more aggressive action or a significant rally in the second half of the year. The guidance issued by Charles River Labs had previously been viewed by the analyst as potentially overambitious.

The note from Baird also mentioned that the ramp-up of the company’s DSA (Discovery (NASDAQ:), Safety and Assurance) segment seems particularly challenging, with the analyst deeming it “wholly undoable,” though the rest of the company’s objectives were considered achievable.

Charles River Laboratories is a global provider of essential products and services to pharmaceutical and biotechnology companies, government agencies, and leading academic institutions to help accelerate their research and drug development efforts. The revised price target from Baird reflects the latest expectations for the company’s financial performance and stock valuation.

In other recent news, Charles River Laboratories has been the subject of several analyst ratings and reviews. The company’s stock was downgraded to a ‘Hold’ from ‘Buy’ by a research firm due to a consistent bearish trend.

This decision was influenced by the company’s first-quarter results, which revealed reductions in revenue, earnings, and operating margin. Barclays also initiated coverage on Charles River Laboratories with an ‘Equalweight’ rating and a price target of $230, citing a need for greater visibility into the company’s performance.

On the other hand, Baird raised the price target for Charles River Laboratories shares to $271.00 while maintaining an ‘Outperform’ rating. The firm’s assessment was based on a comprehensive methodology, which included a variety of financial analyses.

Goldman Sachs initiated coverage on Charles River Laboratories with a ‘Buy’ rating and a price target of $290.00, identifying the company as a leading entity in the preclinical research sector.

However, TD Cowen adjusted its outlook on Charles River Laboratories, reducing the company’s price target from $260.00 to $228.00 due to concerns about the company’s capacity utilization. These recent developments reflect the ongoing challenges and opportunities faced by Charles River Laboratories in the current market environment.

InvestingPro Insights

In light of Baird’s recent outlook adjustment on Charles River Laboratories (NYSE:CRL), it’s worth noting some key metrics and InvestingPro Tips that could provide additional context for investors. With a market capitalization of $10.4 billion and a P/E ratio of 23.32, the company shows a solid valuation in the market. Moreover, analysts predict that Charles River Laboratories will be profitable this year, a view supported by the company’s performance over the last twelve months.

InvestingPro Tips indicate that Charles River Laboratories has had a high return over the last decade, which aligns with Baird’s positive long-term perspective on the company. Additionally, the stock generally trades with low price volatility, which may appeal to investors looking for stable investment opportunities. It’s also worth noting that Charles River Laboratories does not pay a dividend, which could influence investment decisions depending on individual investor strategies.

For further insights and tips, including additional InvestingPro Tips related to Charles River Laboratories, investors can visit https://www.investing.com/pro/CRL. There are 5 more tips available that could help refine investment approaches. Moreover, using the coupon code PRONEWS24 can provide up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, offering access to comprehensive analysis tools and expert insights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.